JPMorgan raised the firm’s price target on Celestica (CLS) to $425 from $410 and keeps an Overweight rating on the shares. The firm upped estimates following the company’s Q1 report.
Meet Samuel – Your Personal Investing Prophet
CSEX: an alternative to margin or options on CLSPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLS: